US Healthcare BillIn listening to a discussion of the US Heathcare Bill on Bloomberg Radio this morning, an interesting tidbit came out...that is, that biologic drugs (e.g. Protoxin) have been granted a 12 year extension for exemption from generic competition. The commentary on this under-the-radar provision of the Bill is that it provides significantly greater certainty and as a result M&A activity in biologics is expected to increase sharply in Q1 2010.
Need to do more DD, but could be good news for PRX.